|drug2547||Placebo of FX06 Wiki||1.00|
|drug2528||Placebo Tablet Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.
Description: DaysMeasure: Proportion of virologically cured (PCR-negative status) as assessed on day six Time: Day 6
Description: DaysMeasure: virologic cure on other study days Time: Day14 and Day 21
Description: DaysMeasure: virologic semiquantitative analysis of changing viral load Time: Day 1 to Day 21
Description: DaysMeasure: proportion of initially symtomatic subjects with disappearance of clinical symptoms Time: Day14 and Day 21
Description: DaysMeasure: proportion of initially asymtomatic subjects with appearance of new clinical symptoms Time: Day14 and Day 21
Description: gradesMeasure: proportions of subjects with potentially medication- related adverse events Time: 7 day
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports